Advertisement

The Latest

An evolving payment landscape, regulatory changes and patient expectations are reshaping orthopedics. Leaders from across the field shared what they believe will have the greatest impact on practices in the year ahead. Editor’s note: Responses have been lightly edited for…

Regional anesthesia is moving from “nice to have” to a core component of orthopedic care by easing pain, accelerating recovery and expanding what’s possible in outpatient surgery. Yet many groups leave clinical and financial value on the table due to…

Presented by:

Presented by

Below is a list of five orthopedic surgeons who have made a positive impact on their organizations and the profession.   Editor’s Note: This is not a list of top surgeons, but rather a list highlighting professional accomplishments. Becker’s does not…

Nearly half of hospital revenue cycle leaders say denials are their top financial concern — outranking labor shortages, reimbursement cuts and analytics gaps. While many teams focus on rework, high-performing hospitals are looking upstream. This short report offers 10 strategies…

Presented by:

Presented by

Between tightening reimbursements, rising operating costs and new technologies, orthopedic leaders are working to deliver quality care while preserving financial and professional stability. Here are five trends keeping orthopedic surgeons up: 1. Inflation and reimbursement headwinds: Orthopedic practices are feeling…

Managing locum tenens at scale is rarely efficient. For one Mid-Atlantic academic medical center, a fragmented approach led to high costs, siloed departments and internal competition for providers. But a centralized, vendor-neutral strategy changed everything. By overhauling its locum tenens…

Presented by:

Presented by

Medtech company Stryker reported sales increases across multiple portfolios in the third quarter, according to financial results posted Oct. 30. Five notes on the company’s financial performance for the third quarter of 2025: 1. Stryker reported an overall net sales…

More than 200 industry leaders have spoken: the 2025 Trends in Specialty Drug Benefits Report, co-sponsored by Genentech and Pharmaceutical Strategies Group (PSG), is here. This executive summary captures how payers are resetting specialty drug strategies and what that means…

Presented by:

Presented by
Advertisement